Ilya Ayzenberg1, Ingo Kleiter2,3. 1. Klinik für Neurologie, St. Josef Hospital Bochum, Ruhr-Universität Bochum, Bochum, Deutschland. ilya.ayzenberg@rub.de. 2. Klinik für Neurologie, St. Josef Hospital Bochum, Ruhr-Universität Bochum, Bochum, Deutschland. 3. Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Milchberg 21, 82335, Berg, Deutschland.
Abstract
BACKGROUND: Antibody-mediated encephalomyelitis, such as neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and glial fibrillary acidic protein (GFAP) antibody-associated astrocytopathy belong to a group of newly described autoimmune diseases. AIM: Presentation of the treatment of antibody-mediated encephalomyelitis with a focus on NMOSD and MOGAD. METHODS: Selective literature search in PubMed taking the consultation version of the S2k guidelines of the German Society of Neurology (DGN) on the diagnosis and treatment of multiple sclerosis (MS), NMOSD and MOG IgG-associated diseases into account. RESULTS: Acute relapses are treated with high-dose steroid pulse therapy or apheresis therapy (plasma exchange or immunoadsorption). It is crucial to start treatment as quickly as possible and apheresis therapy can also be used as first-line treatment under certain conditions. For prophylactic immunotherapy, steroids, classical immunosuppressants and monoclonal antibodies with specific mechanisms of action are used. Eculizumab, inebilizumab and satralizumab are the first drugs approved for NMOSD. Symptomatic treatment and neurorehabilitation are important complementary measures. CONCLUSION: Treatment of antibody-mediated encephalomyelitis differs from treatment of multiple sclerosis and requires specific measures.
BACKGROUND: Antibody-mediated encephalomyelitis, such as neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and glial fibrillary acidic protein (GFAP) antibody-associated astrocytopathy belong to a group of newly described autoimmune diseases. AIM: Presentation of the treatment of antibody-mediated encephalomyelitis with a focus on NMOSD and MOGAD. METHODS: Selective literature search in PubMed taking the consultation version of the S2k guidelines of the German Society of Neurology (DGN) on the diagnosis and treatment of multiple sclerosis (MS), NMOSD and MOG IgG-associated diseases into account. RESULTS: Acute relapses are treated with high-dose steroid pulse therapy or apheresis therapy (plasma exchange or immunoadsorption). It is crucial to start treatment as quickly as possible and apheresis therapy can also be used as first-line treatment under certain conditions. For prophylactic immunotherapy, steroids, classical immunosuppressants and monoclonal antibodies with specific mechanisms of action are used. Eculizumab, inebilizumab and satralizumab are the first drugs approved for NMOSD. Symptomatic treatment and neurorehabilitation are important complementary measures. CONCLUSION: Treatment of antibody-mediated encephalomyelitis differs from treatment of multiple sclerosis and requires specific measures.
Authors: C Costanzi; M Matiello; C F Lucchinetti; B G Weinshenker; S J Pittock; J Mandrekar; P Thapa; A McKeon Journal: Neurology Date: 2011-08-03 Impact factor: 9.910
Authors: Divyanshu Dubey; Shannon R Hinson; Evan A Jolliffe; Anastasia Zekeridou; Eoin P Flanagan; Sean J Pittock; Eati Basal; Daniel A Drubach; Daniel H Lachance; Vanda A Lennon; Andrew McKeon Journal: J Neuroimmunol Date: 2018-04-27 Impact factor: 3.478
Authors: Bruce A C Cree; Jeffrey L Bennett; Ho Jin Kim; Brian G Weinshenker; Sean J Pittock; Dean M Wingerchuk; Kazuo Fujihara; Friedemann Paul; Gary R Cutter; Romain Marignier; Ari J Green; Orhan Aktas; Hans-Peter Hartung; Fred D Lublin; Jorn Drappa; Gerard Barron; Soraya Madani; John N Ratchford; Dewei She; Daniel Cimbora; Eliezer Katz Journal: Lancet Date: 2019-09-05 Impact factor: 79.321
Authors: John J Chen; Eoin P Flanagan; M Tariq Bhatti; Jiraporn Jitprapaikulsan; Divyanshu Dubey; Alfonso Sebastian S Lopez Chiriboga; James P Fryer; Brian G Weinshenker; Andrew McKeon; Jan-Mendelt Tillema; Vanda A Lennon; Claudia F Lucchinetti; Amy Kunchok; Collin M McClelland; Michael S Lee; Jeffrey L Bennett; Victoria S Pelak; Gregory Van Stavern; Ore-Ofe O Adesina; Eric R Eggenberger; Marie D Acierno; Dean M Wingerchuk; Byron L Lam; Heather Moss; Shannon Beres; Aubrey L Gilbert; Veeral Shah; Grayson Armstrong; Gena Heidary; Dean M Cestari; Hadas Stiebel-Kalish; Sean J Pittock Journal: Neurology Date: 2020-06-17 Impact factor: 11.800